AU Patent

AU2011200768B2 — Cladribine regimen for treating multiple sclerosis

Assigned to Merck Serono SA · Expires 2012-09-13 · 14y expired

What this patent protects

Abstract of the invention: The present invention is related to the use of Cladribine for the preparation of a pharmaceutical formulation for the treatment of multiple sclerosis, especially relapsing 5 remitting multiple sclerosis or early secondary progressive multiple sclerosis,…

USPTO Abstract

Abstract of the invention: The present invention is related to the use of Cladribine for the preparation of a pharmaceutical formulation for the treatment of multiple sclerosis, especially relapsing 5 remitting multiple sclerosis or early secondary progressive multiple sclerosis, wherein the preparation is to be the orally administered and wherein re-treatments are possible. 25573001 (GHMabter)

Drugs covered by this patent

Patent Metadata

Patent number
AU2011200768B2
Jurisdiction
AU
Classification
—
Expires
2012-09-13
Drug substance claim
No
Drug product claim
No
Assignee
Merck Serono SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.